Anteris Technologies Global Corp美股招股说明书(2026-05-26版)

This prospectus supplement updates, amends and supplements the prospectus, dated March 13, 2026 (the “Prospectus”), which formspart of our Registration Statement on Form S-1 (Registration No. 333-291821) relating to up to 9,103,796 shares of our commonstock, par value $0.0001 per share (“Common Stock”), which may be offered for sale by the selling stockholders identified under theheading “Selling Stockholders” in the Prospectus. This prospectus supplement is being filed to update, amend and supplement theinformation contained in the Prospectus with information contained in our Current Report on Form 8-K, which was filed with the SECon May 22, 2026 (the “Current Report”).Accordingly, we have attached the Current Report to this prospectus supplement. This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction withthe Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent thatthe information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep thisprospectus supplement with your Prospectus for future reference. Investing in our securities involves a high degree of risk. See the section titled “Risk Factors” in the Prospectus and in thedocuments incorporated by reference in the Prospectus. Neither the SEC nor any state securities commission has approved or disapproved of the securities to be offered pursuant tothe Prospectus or this prospectus supplement or determined if the Prospectus or this prospectus supplement is truthful orcomplete. Any representation to the contrary is a criminal offense. The date of this prospectus supplement is May 26, 2026. UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 8-K CURRENT REPORTPursuant to Section 13 OR 15(d)of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2026 Anteris Technologies Global Corp.(Exact name of registrant as specified in its charter) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrantunder any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Item 1.01 Entry into a Material Definitive Agreement. On May 22, 2026, Anteris Technologies Global Corp. (the “Company”) entered into a Sales Agreement (the “Agreement”) with TDSecurities (USA) LLC (“TD Cowen”). Pursuant to the terms of the Agreement, the Company may offer and sell through TD Cowen,from time to time and at its sole discretion, shares of the Company’s common stock, par value of $0.0001 per share (the “CommonStock”), having an aggregate offering price of up to $250,000,000 (the “Offering”). Subject to the terms and conditions of the Agreement, TD Cowen has agreed to use its commercially reasonable efforts, consistentwith its normal trading and sales practices and applicable law and regulations and the rules of the Nasdaq Stock Market LLC, and theAustralian Securities Exchange, to sell from time to time the Common Stock so designated by the Company, acting as agent and/or asprincipal, in accordance with the Company’s instructions (including any price, time or size limits or other customary parameters orconditions the Company may impose). The Company cannot provide any assurances that it will issue any Common Stock pursuant tothe Agreement. The salesof the Common Stock under the Agreement will be made by any method permitted by law that is deemed an“at the market” offering as defined in Rule 415(a)(4) under the Securities Act of 1933 (the “Securities Act”), including sales madethrough the Nasdaq Global Market (“Nasdaq”), or in negotiated transactions, including block trades. The Agreement provides that thecommission payable to TD Cowen for sales of Common Stock with respect to which TD Cowen acts as sales agent shall be 3.0% ofthe gross proceeds from the sale of such Common Stock sold pursuant to the Agreement. The Agreement con